Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition
Comsa, E., Nguyen, K.A., Loghin, F. et al.
Cisplatin resistance in ovarian cancer remains a complex problem as tumors frequently develop resistance against drugs, a mechanism sometimes mediated by ATP-Binding Cassette transporters. Our goal was to find compounds restricting their inhibition capacity to the cisplatin efflux mediated by ABCC2 pump, among previously identified inhibitors, derived from the 2- indolylmethylenebenzofuranones. Methodology & results: An original method setup allows direct quantitation of platinum by employing cyTOF mass cytometry. Among tested derivatives, some led to a full platinum accumulation and efficiently resensitized cisplatin-resistant A2780 cells to cisplatin while preserving most of the calcein efflux activity.
CyTOF is therefore a powerful and promising method to quantify cisplatin accumulation that may be used in the clinical setting to improve and personalize cancer treatment.
Comsa, E., Nguyen, K.A., Loghin, F. et al. "Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition" Future Medicinal Chemistry (2018): 1,349-60